Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ALKS

Alkermes plc

Dec 08 • 04:00PM ET

25.86

Dollar change -0.30
Percentage change -1.15	%

Healthcare • Drug Manufacturers - Specialty & Generic • Ireland • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	20.95	EPS (ttm)	1.23	Insider Own	1.66%	Shs Outstand	164.38M	Perf Week	6.46%
Market Cap	4.32B	Forward P/E	11.91	EPS next Y	2.17	Insider Trans	0.00%	Shs Float	164.12M	Perf Month	12.26%
Income	214.72M	PEG	0.84	EPS next Q	0.44	Inst Own	98.36%	Short Float / Ratio	4.85% / 3.78	Perf Quarter	-5.76%
Sales	1.59B	P/S	2.71	EPS this Y	390.55%	Inst Trans	-1.28%	Short Interest	7.96M	Perf Half Y	-10.64%
Book/sh	8.13	P/B	3.18	EPS next Y	40.08%	ROA	10.17%	Target Price	31.66	Perf Year	10.08%
Cash/sh	5.33	P/C	4.85	EPS next 5Y	24.80%	ROE	17.91%	52W Range	20.46 - 31.34	Perf YTD	6.46%
Dividend	-	P/FCF	16.98	EPS past 5Y	1.24%	ROI	12.47%	52W High	-17.48%	Beta	0.56
Dividend %	-	Quick Ratio	2.53	Sales past 5Y	4.91%	Gross Margin	82.16%	52W Low	26.39%	ATR	0.82
Employees	2280	Current Ratio	2.91	Sales Q/Q	50.95%	Oper. Margin	13.51%	RSI (14)	59.87	Volatility	3.05% 3.25%
Optionable	Yes	Debt/Eq	0.28	EPS Q/Q	171.34%	Profit Margin	13.50%	Rel Volume	1.06	Prev Close	26.16
Shortable	Yes	LT Debt/Eq	0.27	Earnings	Oct 25 BMO	Payout	-	Avg Volume	2.11M	Price	25.86
Recom	2.00	SMA20	7.34%	SMA50	6.07%	SMA200	-2.50%	Volume	2,224,365	Change	-1.15%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Resumed	JP Morgan	Neutral	$33
Oct-24-23	Upgrade	Evercore ISI	In-line → Outperform
Oct-17-23	Initiated	UBS	Neutral	$31
Nov-03-22	Upgrade	Piper Sandler	Neutral → Overweight	$26 → $30
Oct-14-22	Upgrade	BofA Securities	Underperform → Neutral	$27 → $25
Aug-16-22	Initiated	Piper Sandler	Neutral	$26
Apr-22-22	Resumed	Goldman	Buy	$35
Apr-20-22	Initiated	Goldman	Buy	$35
Jan-27-22	Upgrade	Cantor Fitzgerald	Hold → Overweight	$32
Dec-01-21	Initiated	Citigroup	Neutral	$22
Oct-07-21	Upgrade	Jefferies	Hold → Buy	$36
Sep-02-21	Downgrade	BofA Securities	Neutral → Underperform	$27
Oct-15-20	Upgrade	Mizuho	Neutral → Buy	$19 → $24
Jul-30-20	Downgrade	Goldman	Neutral → Sell	$19 → $15
Feb-14-20	Reiterated	H.C. Wainwright	Neutral	$26 → $25
Feb-14-20	Downgrade	JP Morgan	Overweight → Neutral	$21
Feb-14-20	Downgrade	BofA/Merrill	Buy → Neutral	$31 → $20
Feb-06-20	Initiated	Mizuho	Neutral
Jan-31-20	Upgrade	Wolfe Research	Underperform → Peer Perform
Sep-05-19	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$30 → $20

Show Previous Ratings

Dec-01-23 06:16PM	Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
Nov-29-23 03:15PM	Pharmaceuticals in the Environment (ACCESSWIRE)
12:01PM	The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks (Investor's Business Daily)
Nov-24-23 11:31AM	Why Is Alkermes (ALKS) Down 1.3% Since Last Earnings Report? (Zacks)
Nov-21-23 04:00PM	Alkermes to Participate in Two Upcoming Investor Conferences (PR Newswire)
11:45AM	Loading…
11:45AM	Environmental Protection & Sustainability at Alkermes (ACCESSWIRE)
Nov-20-23 01:45PM	Alkermes Celebrates #Movember for Mens Health Awareness Month (ACCESSWIRE)
Nov-16-23 10:30AM	Alkermes' Waste Optimization Highlights (ACCESSWIRE) +6.03%
Nov-15-23 08:57AM	Mural Oncology wants to paint a new picture in IL-2 after Alkermes spinout (FierceBiotech.com)
07:15AM	Alkermes separates cancer drug business as new company Mural (BioPharma Dive)
07:00AM	Alkermes Completes Separation of Oncology Business (PR Newswire)
Nov-14-23 01:45PM	Our Commitment to Caregivers (ACCESSWIRE)
10:33AM	Alkermes (ALKS) Proprietary Drugs Aid Growth Amid Competition (Zacks)
05:50AM	3 Growth Stocks Set to Dominate the Decade (InvestorPlace)
Nov-13-23 09:50PM	Jim Simons Stock Portfolio: 12 Biggest Healthcare Stocks (Insider Monkey)
12:45PM	Loading…
12:45PM	Product Stewardship and Environmental Impact at Alkermes (ACCESSWIRE)
Nov-10-23 03:00PM	Caring for Caregivers: Alkermes Celebrates National Caregivers Month (ACCESSWIRE)
Nov-09-23 11:12AM	7 Healthcare Stocks That Are Poised to Become the Next Unicorns (InvestorPlace)
Nov-08-23 11:30AM	Environmental Health and Safety at Alkermes (ACCESSWIRE)
Nov-07-23 04:00PM	Alkermes to Participate in the Jefferies London Healthcare Conference (PR Newswire)
Nov-04-23 12:16PM	12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
Oct-31-23 05:08PM	Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement (PR Newswire)
01:30PM	Operating and Growing Responsibly at Alkermes (ACCESSWIRE)
Oct-26-23 12:00PM	Alkermes (ALKS) Down Despite Q3 Earnings & Revenue Beat (Zacks) +5.33%
10:37AM	Alkermes plc (NASDAQ:ALKS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-25-23 12:38PM	Why Alkermes Stock Is Sinking Today (Motley Fool) -7.39%
09:30AM	Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
07:23AM	Alkermes: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Alkermes plc Reports Third Quarter 2023 Financial Results (PR Newswire)
Oct-24-23 09:51AM	Foot Locker downgraded, Amazon initiated: Wall Street's top analyst calls (The Fly)
04:00PM	Loading…
Oct-23-23 04:00PM	Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone. (Investor's Business Daily) -9.59%
02:00PM	Alkermes CEO Reflects on Living Company Purpose (ACCESSWIRE)
08:00AM	Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress (PR Newswire)
Oct-19-23 10:01AM	Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-18-23 06:15PM	Alkermes (ALKS) Dips More Than Broader Market: What You Should Know (Zacks)
04:00PM	Alkermes to Report Third Quarter Financial Results on October 25, 2023 (PR Newswire)
Oct-16-23 12:30PM	Celebrating Global Diversity Awareness Month at Alkermes (ACCESSWIRE)
Oct-13-23 10:45AM	Take Time During Mental Health Awareness Week To Review These Resources (ACCESSWIRE)
Oct-11-23 12:00PM	Alkermes Proudly Announces Release of 2023 Corporate Responsibility Report (ACCESSWIRE)
Oct-10-23 05:00PM	Mural Oncology to Host Investor Webcast on October 17 (PR Newswire)
07:00AM	Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress (PR Newswire)
Sep-21-23 01:00PM	Alkermes Pauses To Recognize National Ovarian Cancer Awareness Month (ACCESSWIRE)
Sep-19-23 11:05AM	Alkermes Pathways Research Awards Is Now Accepting Applications! (ACCESSWIRE)
Sep-18-23 01:15PM	Alkermes Commemorates World Suicide Prevention Day (ACCESSWIRE)
Sep-15-23 06:15PM	Alkermes (ALKS) Stock Moves -0.84%: What You Should Know (Zacks)
Sep-13-23 10:50AM	For Potential Alkermes Buyers, There's a Key Price Level to Watch (TheStreet.com)
Sep-11-23 07:00AM	Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress (PR Newswire)
Sep-08-23 06:15PM	Alkermes (ALKS) Stock Sinks As Market Gains: What You Should Know (Zacks)
Sep-07-23 03:15PM	Alkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards(R) Program (ACCESSWIRE)
11:31AM	Novavax (NVAX) Up 36.8% Since Last Earnings Report: Can It Continue? (Zacks)
09:30AM	Alkermes (ALKS) Recently Broke Out Above the 50-Day Moving Average (Zacks)
07:00AM	Alkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards® Program (PR Newswire)
Sep-06-23 09:50AM	Here's Why Alkermes (ALKS) is a Strong Momentum Stock (Zacks)
Sep-05-23 04:00PM	Alkermes to Participate in Two Upcoming Investor Conferences (PR Newswire)
Sep-01-23 06:30PM	Sleep Number, Newell Brands, and More Stocks See Action From Activist Investors (Barrons.com)
11:31AM	Acadia (ACAD) Down 0.7% Since Last Earnings Report: Can It Rebound? (Zacks)
Aug-31-23 02:45PM	Alkermes Announces Recipients of 2023 Alkermes Inspiration Grants(R) Program (ACCESSWIRE)
11:02AM	Alkermes (ALKS) Grants Teva License to Market Generic Drug (Zacks)
07:00AM	Alkermes Announces Recipients of 2023 Alkermes Inspiration Grants® Program (PR Newswire)
Aug-30-23 07:00AM	Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation (PR Newswire) +7.10%
Aug-28-23 10:35AM	Alkermes Honors Women's Equality Day (ACCESSWIRE)
Aug-25-23 11:31AM	Why Is Alkermes (ALKS) Down 9% Since Last Earnings Report? (Zacks)
Aug-21-23 10:45AM	Back to College? Talk to Your Student About Alcohol (ACCESSWIRE)
Aug-10-23 05:21AM	3 Top Biotech Stocks Defying the Bear Market (Motley Fool)
Aug-09-23 08:32AM	Should Weakness in Alkermes plc's (NASDAQ:ALKS) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? (Simply Wall St.)
Aug-04-23 12:36PM	Puma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales Outperform (Zacks)
Jul-27-23 10:24AM	Alkermes (ALKS) Q2 Earnings & Revenues Beat Estimates (Zacks)
Jul-26-23 11:05AM	GSK Beats on Q2 Earnings & Sales, Raises 2023 Guidance (Zacks)
09:30AM	Compared to Estimates, Alkermes (ALKS) Q2 Earnings: A Look at Key Metrics (Zacks)
08:15AM	Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates (Zacks)
07:11AM	Alkermes: Q2 Earnings Snapshot (AP Finance)
07:00AM	Alkermes plc Reports Second Quarter 2023 Financial Results (PR Newswire)
Jul-25-23 11:21AM	Biogen (BIIB) Beats on Q2 Earnings & Sales, Announces Job Cuts (Zacks)
Jul-24-23 01:45PM	Alkermes Awarded 2023 Platinum Bell Seal for Workplace Mental Health (ACCESSWIRE)
10:44AM	Gilead (GILD) Ends Myelodysplastic Syndromes Study on Magrolimab (Zacks)
Jul-21-23 12:05PM	Vir Biotechnology (VIR) Down on Influenza Study Failure (Zacks)
09:30AM	Alkermes (ALKS) to Report Q2 Earnings: What's in the Cards? (Zacks)
Jul-20-23 10:02AM	Will Alnylam Pharmaceuticals (ALNY) Report Negative Q2 Earnings? What You Should Know (Zacks)
Jul-19-23 04:00PM	Alkermes to Report Second Quarter Financial Results on July 26, 2023 (PR Newswire)
11:30AM	Alkermes Celebrates Pride Month (ACCESSWIRE)
10:01AM	Alkermes (ALKS) Earnings Expected to Grow: Should You Buy? (Zacks)
Jul-17-23 11:40AM	Gilead's (GILD) Veklury Gets FDA Nod for Label Expansion (Zacks)
11:15AM	Celebrating 15 Years of Alkermes in Action (ACCESSWIRE)
Jul-13-23 09:40AM	Are Medical Stocks Lagging Alkermes (ALKS) This Year? (Zacks)
07:56AM	Alkermes plc (NASDAQ:ALKS) Shares Could Be 45% Below Their Intrinsic Value Estimate (Simply Wall St.)
Jul-11-23 08:44AM	Implied Volatility Surging for Alkermes (ALKS) Stock Options (Zacks)
Jul-10-23 09:55AM	Here's Why Alkermes (ALKS) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Jul-06-23 08:00AM	How To Trade Biotech Stocks: Can These Three Tips Help You Make More Profits? (Investor's Business Daily)
Jul-04-23 07:56AM	Here's Why You Should Add Alkermes (ALKS) to Your Portfolio (Zacks)
Jun-29-23 10:50AM	Alkermes Shareholders Re-Elect All Seven Company Director Nominees at 2023 Annual General Meeting of Shareholders (PR Newswire)
10:09AM	Alkermes wins battle against Sarissa in closely watched boardroom fight (Reuters)
09:57AM	UPDATE 3-Alkermes wins battle against Sarissa in closely watched boardroom fight (Reuters)
09:20AM	Alkermes beats back board room challenge from Sarissa Capital Management, all directors re-elected - source (Reuters)
Jun-28-23 07:30AM	Sarissa Capital Urges Alkermes Shareholders to Vote "FOR" Sarah Schlesinger and "WITHHOLD" Incumbent Director Richard Gaynor (Business Wire)
Jun-27-23 01:45PM	Tips for Finding LGBTQ+ Competent Mental Health Care (ACCESSWIRE)
09:40AM	Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-26-23 07:37AM	Sarissa Issues Presentation Highlighting Sarissa Nominees Are Qualified to Create Value for Alkermes Shareholders (Business Wire)
07:00AM	Recently-Appointed Independent Directors of Alkermes Issue Open Letter to Shareholders (PR Newswire)
Jun-22-23 06:25AM	Independent Proxy Advisory Firm ISS Agrees With Sarissa Capital That Shareholders Interests Would Be Best Served With Direct Shareholder Representation on the Alkermes Board (Business Wire)
Jun-21-23 02:15PM	DYK: The LGBTQ+ Community Is at Greater Risk for Substance Abuse (ACCESSWIRE)

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LAURENCIN CATO T	Director	Jun 08	Option Exercise	22.97	2,638	60,595	10,117	Jun 08 04:31 PM
LAURENCIN CATO T	Director	Jun 08	Sale	31.85	2,638	84,020	7,479	Jun 08 04:31 PM
LAURENCIN CATO T	Director	Jun 07	Option Exercise	22.97	2,800	64,316	10,279	Jun 07 05:12 PM
LAURENCIN CATO T	Director	Jun 07	Sale	31.50	2,800	88,200	7,479	Jun 07 05:12 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	May 30	Option Exercise	20.43	19,634	401,123	68,118	May 30 08:16 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	May 30	Sale	28.93	27,134	784,862	40,984	May 30 08:16 PM
Wysenski Nancy	Director	May 09	Option Exercise	31.13	41,250	1,284,112	57,079	May 10 04:34 PM
Wysenski Nancy	Director	May 09	Sale	31.24	41,250	1,288,786	15,829	May 10 04:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALKS

Alkermes plc

Upgrade your FINVIZ experience